Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
Open accessThe DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Abstract
AIMS/HYPOTHESIS: Metformin is the most-prescribed oral medication to lower blood glucose worldwide. Yet previous systematic reviews have raised doubts about its effectiveness in reducing risk of cardiovascular disease, the most costly complication of type 2 diabetes. We aimed to systematically identify and pool randomised trials reporting cardiovascular outcomes in which the effect of metformin was 'isolated' through comparison to diet, lifestyle or placebo. METHODS: We performed an electronic literature search of MEDLINE, EMBASE and the Cochrane Library. We also manually screened the reference lists of previous meta-analyses of trials of metformin identified through a MEDLINE search. We included randomised controlled trials of adults with type 2 diabetes comparing any dose and preparation of oral metformin with no intervention, placebo or a lifestyle intervention and reporting mortality or a cardiovascular outcome. RESULTS: We included ten articles reporting 13 trials (including a total of 2079 individuals with type 2 diabetes allocated to metformin and a similar number to comparison groups) of which only four compared metformin with placebo and collected data on cardiovascular outcomes. Participants were mainly white, aged ≤65 years, overweight/obese and with poor glycaemic control. Summary estimates were based on a small number of events: 416 myocardial infarctions/ischaemic heart disease events in seven studies and 111 strokes in four studies. The UK Prospective Diabetes Study (UKPDS) contributed the majority of data to the summary estimates, with weights ranging from 52.3% for myocardial infarction to 70.5% for stroke. All outcomes, with the exception of stroke, favoured metformin, with limited heterogeneity between studies, but none achieved statistical significance. Effect sizes (Mantel-Haenszel RR) were: all-cause mortality 0.96 (95% CI 0.84, 1.09); cardiovascular death 0.97 (95% CI 0.80, 1.16); myocardial infarction 0.89 (95% CI 0.75, 1.06); stroke 1.04 (95% CI 0.73, 1.48); and peripheral vascular disease 0.81 (95% CI 0.50, 1.31). CONCLUSIONS/INTERPRETATION: There remains uncertainty about whether metformin reduces risk of cardiovascular disease among patients with type 2 diabetes, for whom it is the recommended first-line drug. Although this is mainly due to absence of evidence, it is unlikely that a definitive placebo-controlled cardiovascular endpoint trial among people with diabetes will be forthcoming. Alternative approaches to reduce the uncertainty include the use of electronic health records in long-term pragmatic evaluations, inclusion of metformin in factorial trials, publication of cardiovascular outcome data from adverse event reporting in trials of metformin and a cardiovascular endpoint trial of metformin among people without diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram [40]](https://figures.cochat.ai/paper-figures/21d83ef63bbb4a5890ce9f40e21450f3/impact-of-metformin-on-cardiovascular-disease-a-meta-analysis-of-randomised-figure-1.jpg)







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In meta-analyses of 13 randomized clinical trials evaluating the CV effects of metformin vs. placebo or active control, including the data from the UKPDS, none of the differences in assessed CV outcomes was statistically significant.184”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [184]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Excepting glimepiride, which was assessed for CV safety and efficacy head-to-head against linagliptin in the CAROLINA trial, and gliclazidemodified release, which was compared with usual care (that could have included treatment with a sulphonylurea other than gliclazide) in the ADVANCE trial, dedicated CV safety assessments have not been conducted for the other sulphonylureas.132,173,174,184”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [184]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“12 weeks of treatment with licogliflozin led to a numerically greater reduction in liver lipid content, body weight (4.2 %) and HbA1c (1 %) compared to RCTs with sole SGLT2I treatment (Table 1) [161,163].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [163]
Experimental — accuracy not yet measuredIn the citing paper
“This Class IIa recommendation for metformin is based on the weight of opinion rather than the weight of evidence; results from meta-analyses of observational studies suggest associations with better CV outcome, but this is not supported by results from meta-analyses restricted to randomized trials in patients with T2DM and ASCVD, where no statistically significant effect of metformin has been”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [184]
In the citing paper
“The pooled HRs (95% CIs) were: all-cause mortality 0.96 (0.84-1.09);CV death 0.97 ( 0.80-1.16); MI 0.89 (0.75-1.06); stroke 1.04 (0.73-1.48); and peripheral vascular disease 0.81 (0.50-1 31).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [184]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Metformin monotherapy for type 2 diabetes mellitus
Saenz, A., Fernandez-Esteban, I., Mataix, A., Ausejo Segura, M., Roqué i Figuls, M., & Moher, D. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002966.pub3 · Cited by 308
RetractedPreferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“Metformin reduced the incidence of diabetes by 31% among people with glucose levels just below the diagnostic threshold in the US Diabetes Prevention Programme [36], and by 26% in the Indian equivalent [37].”
BackgroundEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 10×
“studies [19, 21] to 15 years [27]) and poorly controlled diabetes (average baseline HbA1c was less than 8% [63.”
BackgroundMethodInfluentialLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“This contrasts with the evidence now available for newer and more expensive glucose-lowering drugs, such as empagliflozin [34] and liraglutide [10], and of course for medications targeting different risk factors, for example statins.”
Background
Cited by
Items 201–300 of 398
Maulidiani, M., Abas, F., Rudiyanto, R., Kadir, N. H. A., Zolkeflee, N. K. Z., & Lajis, N. H. (2019) · Microchemical Journal · doi:10.1016/j.microc.2019.104513 · Cited by 12
New Insight into Metformin Mechanism of Action and Clinical Application
Yan, Y., Kover, K. L., & Moore, W. V. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.91148 · Cited by 13
Carrasco-Sánchez, F. J., Rodríguez, J. M. F., Ena, J., Gómez‐Huelgas, R., & Carretero‐Gómez, J. (2020) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2020.06.009 · Cited by 17
Cardiovascular Safety of Antihyperglycemic Agents: “Do Good or Do No Harm”
Manolis, A. S., Manolis, T. A., & Manolis, A. S. (2018) · Drugs · doi:10.1007/s40265-018-0985-4 · Cited by 12
Shariat‐Madar, Z., & Mahdi, F. (2025) · Molecules · doi:10.3390/molecules30224448 · Cited by 18
“However, meta-analyses cast a shadow on the effectiveness of metformin in reducing the risk of adverse cardiovascular outcomes [70].”
Metabolic Effects of Metformin in Humans
Adeva‐Andany, M. M., Rañal-Muíño, E., Fernández‐Fernández, C., Pazos-García, C., & Vila-Altesor, M. (2018) · Current Diabetes Reviews · doi:10.2174/1573399814666181009125348 · Cited by 12
Carrasco-Sánchez, F. J., Rodríguez, J. M. F., Ena, J., Gómez‐Huelgas, R., & Carretero‐Gómez, J. (2020) · Revista Clínica Española · doi:10.1016/j.rce.2020.06.005 · Cited by 13
Ribeiro, F. M., Ratti, B. A., Rando, F. D. S., Fernandez, M. A., Ueda‐Nakamura, T., Silva, S. D. O., & Nakamura, C. V. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111387 · Cited by 12
Rottura, M., Scondotto, G., Barbieri, M. A., Sorbara, E. E., Nasso, C., Marino, S., Scoglio, R., Mandraffino, G., Pallio, G., Irrera, N., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.749686 · Cited by 12
Sun, M., Liu, C., Bai, H., Wei, Y., Zhang, W., Liu, H., Li, Y.-J., Liu, L., Wang, Y., Tong, Y.-X., et al. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2125574 · Cited by 12
“Metformin has been used in clinical practice for more than 60years, and sufficient data are available to prove its safety [22].”
BackgroundMetformin adherence and the risk of cardiovascular disease: a population-based cohort study
Yu, S.-F., Hong, C., Chen, W., Chan, L., & Chien, L. (2023) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223231163115 · Cited by 12
Novel ABCA1 peptide agonists with antidiabetic action
Azhar, S., Bittner, S., Hu, J., Shen, W., Cortez, Y., Xiao, H., Han, L., Lagerstedt, J. O., Kraemer, F. B., & Johansson, J. O. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.09.011 · Cited by 11
“…because of improvement in CVD risk factors such as lowering of smoking prevalence, and total cholesterol and blood pressure (Fox et al., 2007), a smaller reduction has occurred in patients with diabetes than patients without diabetes (Gaede et al., 2003; Go et al., 2013; Griffin et al., 2017).”
BackgroundAlalami, H., Sathyapalan, T., & Atkin, S. L. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818805674 · Cited by 12
Conde, A. C., Martín, D. M., Arrarte, V., Campuzano, R., Dalmau, R., Olmo, M. R. F., García–Moll, X., Gómez‐Doblas, J. J., Gorgojo, J. J., Mazón, P., et al. (2019) · REC CardioClinics · doi:10.1016/j.rccl.2019.04.005 · Cited by 12
Wang, H., Wang, C., Lu, Y. Q., Yan, Y., Leng, D., Tian, S., Zheng, D., Wang, Z., & Bai, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00614 · Cited by 10
“With an alteration in treatment patterns, a progressive protective effect of metformin on the cardiovascular system occurs via energy metabolism, mitochondrial energy metabolism or other pathways were increased (Griffin et al., 2017; Sun and Yang, 2017).”
BackgroundKim, M. H., Oh, H. J., Kwon, S. H., Jeon, J. S., Noh, H., Han, D. C., Kim, H., & Ryu, D. (2021) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.20.222 · Cited by 11
Management of diabetes today: An exciting confusion
Ceriello, A. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108129 · Cited by 14
Liu, F., & Cai, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1583267 · Cited by 10
Azimian, L., Weerasuriya, N. M., Munasinghe, R., Song, S., Lin, C., & You, L. (2023) · Cell Biochemistry and Function · doi:10.1002/cbf.3778 · Cited by 13
Ihana‐Sugiyama, N., Sugiyama, T., Tanaka, H., Ueki, K., Kobayashi, Y., & Ohsugi, M. (2019) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13171 · Cited by 10
“Metformin's cardiovascular benefits, however, have been reappraised recently, especially since its evidence was mainly derived from the UK Prospective Diabetes Study (UKPDS) results.(2) As for Asian countries, priority of metformin use is different.”
BackgroundIshii, H. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13799 · Cited by 12
Metformin's Impact on the Microvascular Response to Insulin
Love, K. M., Barrett, E. J., & Horton, W. B. (2022) · Endocrinology · doi:10.1210/endocr/bqac162 · Cited by 10
Hsu, C., Hsuan, C., Liao, D., Chang, J. K.-J., Chang, A. J.-W., Hee, S., Lee, H.-L., & Teng, S. I. F. (2023) · Life · doi:10.3390/life13041024 · Cited by 14
“In contrast, meta-analyses of RCTs reported no benefit of metformin on HF in diabetic patients [72,73].”
ResultIglay, K., Sawhney, B., Fu, A. Z., Fernandes, G. F., Crutchlow, M. F., Rajpathak, S. N., & Khunti, K. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.107 · Cited by 9
“27,28 A recent US study found that up-titration of metformin was as effective as adding a second T2DM drug in terms of the probability of glycaemic control after 6 months.”
Lavalle-Cobo, A., Masson, W., Lobo, M., Masson, G., & Molinero, G. (2021) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00479-1 · Cited by 9
Elbarbary, N. S., Ismail, E. A. R., & Ghallab, M. A. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109857 · Cited by 9
Corbacho-Alonso, N., Rodríguez‐Sánchez, E., Sastre-Oliva, T., Mercado‐García, E., Perales-Sánchez, I., Juárez-Alia, C., Lopez-Almodovar, L. F., Padial, L. R., Tejerina, T., Mouriño-Álvarez, L., et al. (2023) · Antioxidants · doi:10.3390/antiox12051024 · Cited by 9
“Recently, a meta-analysis suggested that the CV effects of metformin could be smaller than those reported by the United Kingdom Prospective Diabetes Study in 1995 [14]; however, this should be interpreted with caution, because there had only been a small number of randomized controlled trials to be included in the met…”
ResultUnderstanding the cardiovascular risk with non-insulin antidiabetic drugs
Athyros, V. G., Imprialos, K. P., Stavropoulos, K., Sahinidis, A., & Doumas, M. N. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1586881 · Cited by 10
Remission of type 2 diabetes: position statement of the Italian society of diabetes (SID)
Capoccia, D., Leonetti, F., Natali, A., Tricò, D., Perrini, S., Sbraccia, P., Guglielmi, V., & On behalf of the Italian Society of Diabetes (SID) (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02317-x · Cited by 11
“Finally, in the long term, as highlighted in the 20-year follow-up of the DPP (DPPOS, Diabetes Prevention Program Outcomes Study), neither metformin nor lifestyle intervention modified cardiovascular risk [38, 45] in line with previous studies [46–49].”
ResultEl-Abasy, H. M., Elsaid, M. E. A., El-Kader, E. M. A., & Shehatou, G. S. G. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123115 · Cited by 12
Malin, S. K., Heiston, E. M., Battillo, D. J., Ragland, T. J., Gow, A. J., Shapses, S. A., Shah, A. M., Patrie, J. T., & Barrett, E. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf551 · Cited by 10
Metformin Protects Cardiovascular Health in People With Diabetes
Chen, C., Yuan, S., Zhao, X., Qiao, M., Li, S., He, N., Huang, L., & Lyu, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.949113 · Cited by 9
Cognitive impairment in type 2 diabetes mellitus: prospects for the use of metformin
Pashkovska, N. V. (2023) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.19.3.2023.1274 · Cited by 10
Napoli, R., Formoso, G., Piro, S., Targher, G., Consoli, A., & Purrello, F. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.07.012 · Cited by 9
Chin, S. O., Ha, I. G., Rhee, S. Y., Jeong, S. J., Chon, S., Kim, S. H., Ahn, K. J., Baik, S. H., Park, Y., Nam, M. S., et al. (2020) · International Journal of Endocrinology · doi:10.1155/2020/9879517 · Cited by 10
Advantages of the use of metformin in patients with impaired uric acid metabolism
Елисеев, М. С., Паневин, Т. С., Zhelyabina, O. V., & Nasonov, E. L. (2021) · Terapevticheskii arkhiv · doi:10.26442/00403660.2021.05.200795 · Cited by 8
“Полученные данные свидетельствуют о том, что МФ снижает риск общей смертности на 16% [24].”
Wang, M., Pan, H.-Y., Huang, Y., Wu, L., Wang, P.-C., Hsu, Y., Lin, T., Lin, C., Lai, J., & Lee, C.-H. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.45854 · Cited by 8
Bubak, M. P., Davidyan, A., O’Reilly, C. L., Mondal, S. A., Keast, J., Doidge, S. M., Borowik, A., Taylor, M. E., Volovičeva, E., Kinter, M. T., et al. (2024) · Aging Cell · doi:10.1111/acel.14235 · Cited by 10
“Metformin has over 50 years of safety data, is cost-effective, and is associated with a decreased risk of mortality and morbidity for diseases such as cardiovascular disease, cancer, and demen - tia (Chaudhari et al., 2020 ; Griffin et al., 2017; Li et al., 2018).”
Positioning newer drugs in the management of type 2 diabetes
Prattichizzo, F., & Ceriello, A. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00022-x · Cited by 8
Lv, Y., Chen, L., Li, L., Liao, Z., Fang, Z., Cheng, L., & Peng, F. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1535401 · Cited by 10
Yu, L., Zhou, Y., Wang, L., Zhou, X., Sun, J., Xiao, J., Xu, X., Larsson, S. C., Yuan, S., & Li, X. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.814457 · Cited by 8
“, 2019), which is wellrecognized as the first-line medication for diabetes (Suissa and Azoulay, 2012; Griffin et al., 2017).”
BackgroundDiabetes and Stroke: Impact of Novel Therapies for the Treatment of Type 2 Diabetes Mellitus
Vieira, I. H., Carvalho, T., Saraiva, J. C., Gomes, L., & Paiva, I. (2024) · Biomedicines · doi:10.3390/biomedicines12051102 · Cited by 9
“A 2017 metanalysis documented the benefit of metformin on all cardiovascular endpoints except stroke, but without reaching statistical significance [92].”
BackgroundGlucosuria and all-cause mortality among general screening participants
Check”, F. T. “. O. T. C. H. C. S. F. C. K. D. (. B. O. T. I. R. A. B. S. H., Iseki, K., Konta, T., Asahi, K., Yamagata, K., Fujimoto, S., Tsuruya, K., Narita, I., Kasahara, M., Shibagaki, Y., et al. (2018) · Clinical and Experimental Nephrology · doi:10.1007/s10157-017-1528-0 · Cited by 9
Kato, E. T., Das, S. R., & McGuire, D. K. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.12.010 · Cited by 9
Scheen, A. J. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.11.001 · Cited by 8
Tanaka, A., Shimabukuro, M., Teragawa, H., Okada, Y., Takamura, T., Taguchi, I., Toyoda, S., Tomiyama, H., Ueda, S., Higashi, Y., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01352-0 · Cited by 10
Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus
Hu, Y. (2019) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2019.01.001 · Cited by 7
Singh, A. K., & Singh, R. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108536 · Cited by 7
Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?
Rhee, E. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.304 · Cited by 12
“However, a meta-analysis that included the results of this trial and other, smaller trials concluded that owing to limited data, there was uncertainty as to whether metformin reduces the risk of CVD [16].”
ResultSenolytics: The Modern Snake Oil?
Morley, J. E. (2019) · The journal of nutrition health & aging · doi:10.1007/s12603-019-1202-1 · Cited by 8
“Metformin is the drug of choice for the treatment of diabetes and in those patients metformin may reduce cardiovascular disease (22-24).”
BackgroundMetformin suppresses atherosclerosis by dampening extramedullary myelopoiesis
Lee, M. K., Cooney, O. D., Zhu, Y., Zhang, Y., Lin, X., Onda, D.-A., Galić, S., Kemp, B. E., Murphy, A. J., & Loh, K. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00056.2025 · Cited by 7
The effect of metformin on cardiovascular markers in female mice consuming a high fat diet
de Alwis, N., Binder, N. K., Mangwiro, Y. T. M., Pritchard, N., Beard, S., Kaitu’u‐Lino, T. J., Brownfoot, F., & Hannan, N. J. (2022) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2022.10.006 · Cited by 6
Sun, R., Yuan, L., Shen, Y., Shen, Z., Ding, B., & Ma, J. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s423322 · Cited by 7
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6755 · Cited by 7
Lambadiari, V., Dimitriadis, G., & Kadoglou, N. P. E. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9690-3 · Cited by 6
“of metformin on cardiovascular disease due to a lack of largescale cardiovascular endpoint data [26].”
BackgroundDomecq, J. P., Prutsky, G. J., Elraiyah, T. A., Wang, Z., Mauck, K. F., Brito, J. P., Undavalli, C., Sundaresh, V., Prokop, L. J., Montori, V. M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01269 · Cited by 8
Metformina: Uso clínico y actualización
Vicente, I. D., Betancourt, M. O., Rodríguez, L. A., Gallardo, S. B. R., Guifarro, M. A. R., & Ávila-Turcios, D. M. (2019) · Revista Médica Hondureña · doi:10.5377/rmh.v87i1.11935 · Cited by 9
Yen, F., Wei, J. C., Chiu, L., Hsu, C., & Hwu, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.919881 · Cited by 6
“However, a metaanalysis of randomized clinical trials of metformin use in patients with T2DM disclosed a neutral effect in reducing CVD risk (Griffin et al., 2017).”
BackgroundDiabetes and COVID-19: a bitter nightmare
Hasanzad, M., Larijani, B. A., & Meybodi, H. R. A. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-022-00994-5 · Cited by 6
Wong, H. J., Lin, N., Teo, Y. N., Syn, N. L. X., Teo, Y. H., & Sia, C. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00640-w · Cited by 8
“These findings are consistent with previous studies evaluating the effects of metformin and SGLT2 inhibitors on mortality and cardiovascular outcomes [42–45].”
Gallbladder Polyps Increase the Risk of Ischaemic Heart Disease Among Korean Adults
Lee, Y., Park, B., Hong, K., & Jung, D. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.693245 · Cited by 5
Chen, H., Yuan, Y., Zhang, Y., Liu, X., Chen, Q., Liu, C., & Yao, Q. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04235-4 · Cited by 6
“Although there are reports [16, 17] indicating that the drug has a glu-cose-independent function that improves the prognosis of stroke patients, its mechanism in contemporary research remains unclear.”
A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus
AlHabeeb, W., Elasfar, A., Kinsara, A. J., Aljizeeri, A. H., Jelaidan, I., Alghalayini, K. W., AlKheraiji., M. F., Akbar, M. A. J., Lawand, S., Alyousif, S. M., et al. (2024) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1407 · Cited by 11
“A meta-analysis of results from 13 RCTs con fi rmed that metformin did not signi fi cantly impact CV outcomes either when compared to placebo or an active con-trol [135].”
Shabil, M., Bushi, G., Yadav, A., Ahmed, M., Kishore, J., Lekamwasam, S., & Joshi, A. (2023) · The Evidence · doi:10.61505/evidence.2023.1.1.3 · Cited by 5
Dalan, R. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000201 · Cited by 6
Κender, Ζ., Groener, J. B., Reismann, P., & Kopf, S. (2019) · Orvosi Hetilap · doi:10.1556/650.2019.31547 · Cited by 7
“teljeskoleszterin- és LDL-koleszterin-szintekre gyakorolt pozitív hatását írták le, a szérumtriglicerid, a HDLkoleszterin és más rizikófaktorok csökkentése nélkül [16, 18, 23].”
Cardiovascular outcome trials of glucose-lowering therapies
Khunti, K., Davies, M. J., & Seidu, S. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2020.1763796 · Cited by 7
Landgraf, R., Kellerer, M., Aberle, J., Fach, E.-M., Gallwitz, B., Hamann, A., Joost, H., Klein, H., Müller‐Wieland, D., Nauck, M. A., et al. (2019) · Der Diabetologe · doi:10.1007/s11428-019-0459-7 · Cited by 5
“[24] Griffin SJ, Leaver JK, Irving GJ et al.”
BackgroundVargas, J. M., Rico-Fontalvo, J. E., Enrique Melgarejo, R., Castillo, G. A., Rincón, A. R., Gómez, A. M., Rojas, S. M., & Ibatá, L. (2020) · Revista Colombiana de Nefrología · doi:10.22265/acnef.7.1.372 · Cited by 14
Barinda, A. J., Arozal, W., & Yuasa, S. (2022) · Medical Journal of Indonesia · doi:10.13181/mji.rev.226064 · Cited by 4
Huang, C., & Lee, J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051387 · Cited by 4
“Meta-analyses have not provided clear evidence of the cardiovascular benefits of metformin for individuals with T2DM and there are limited data on its effects on renal outcomes [12,13].”
BackgroundMethodLandgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00921-5 · Cited by 8
Simeone, P., Liani, R., Bologna, G., Tripaldi, R., Castelnuovo, A. F. D., Simeone, P., D’Ardes, D., Miscia, S., Cipollone, F., Marchisio, M., et al. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.09.010 · Cited by 4
Wang, M., Li, M., Wang, L., Wang, F., Cao, X., Li, S., & Zheng, Z. (2024) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.04.009 · Cited by 4
Когнітивні порушення при цукровому діабеті типу 2: роль гіпоглікемізуючої терапії
Pashkovska, N. V. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.14.1.2018.127097 · Cited by 10
New antihyperglycaemic agents and cardiovascular disease: let's be optimistic
Pafili, K., Rizzo, M., & Παπάνας, Ν. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000524 · Cited by 6
Schweighofer, N., Genser, B., März, W., Kleber, M. E., Trummer, O., Pieber, T. R., & Obermayer-Pietsch, B. M. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s235663 · Cited by 4
Koskinas, K. C., Melmer, A., Steiner, N., Gübeli, A., Wilhelm, M., & Laimer, M. W. (2021) · Praxis · doi:10.1024/1661-8157/a003589 · Cited by 7
Li, T. X., & Ma, H. (2020) · JAMA Surgery · doi:10.1001/jamasurg.2020.3769 · Cited by 4
Zhou, R., Wu, Q., Qian, H., Wang, L., Liu, G., Zhang, B., Wu, W., & Zhang, S. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm26835 · Cited by 7
“[50] evaluated the cardiovascular outcomes of metformin and concluded that while it is considered safe and potentially beneficial for CAD, evidence from long-term studies remains inconclusive due to limitations in study de-sign and small sample sizes.”
Effects of metformin treatment on the risk of acute myocardial infarction
Chang, C., Chou, Y., Yang, T., Chang, J., & Sun, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-13211-z · Cited by 5
Bahardoust, M., Hadaegh, F., Mehrabi, Y., Delpisheh, A., & Khalili, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-89721-7 · Cited by 5
“Griffin et al., 47 did not report a clear drug-meaning relationship between metformin monotherapy as the first-line drug and reducing the risk of cardiovascular disease in diabetic patients.”
Diabetic Control Agents and Their Impact on Cardiac Surgery Patients: A Clinical Overview
O’Neill, P., Leung, M. S. T., Visser, R. A. B., & Harky, A. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420963688 · Cited by 3
“Similarly, other meta-analysis has found strong association between metformin and risk of cardiovascular related mortality.(29) Contrastingly, there are studies that found Metformin’s effectiveness in reducing mortality, where one study compared the effects of perioperative metformin and unspecified non-metformin medi…”
ResultComparative Analysis of Metformin and Imeglimin: Exploring Therapeutic Implications
Nagendra, L., Bhattacharya, S., Bhat, S., Dutta, D., Kamrul-Hasan, A. B. M., & Kalra, S. (2024) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_2_24 · Cited by 6
Evaluation of the effect of metformin as a radiosensitiser in solid tumours: A systematic review
Portillo, E. G.-D., Olivares-Hernández, A., Corral-Gudino, L., Corvo-Félix, L., Hernández, L. B., Posado-Domínguez, L., Jiménez, D. L., González‐Sarmiento, R., del Barco, E., Sánchez, E. F., et al. (2025) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2025.100930 · Cited by 6
Metformin: a review on its ethnobotanical source and versatile uses
Asif, M., Acharya, M., & Imran, M. (2020) · Egyptian Pharmaceutical Journal · doi:10.4103/epj.epj_50_19 · Cited by 3
Polypharmacology in Old Drug Rediscovery: Drug Repurposing
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_13 · Cited by 7
Krentz, A. J., & Rodriguez‐Araujo, G. (2017) · Pharmaceutical Medicine · doi:10.1007/s40290-017-0209-3 · Cited by 3
The impact of glucose-lowering medications on cardiovascular disease
Avogaro, A., de Kreutzenberg, S. V., & Fadini, G. P. (2017) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000139 · Cited by 5
Preventative Strategies of Atherosclerotic Cardiovascular Disease
Prado, K. B., & Napierkowski, D. B. (2020) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2019.09.020 · Cited by 4
Virginia, D. M., Wahyuningsih, M. S. H., & Nugrahaningsih, D. A. A. (2021) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2021.6213 · Cited by 5
Diabetes and Kidney disease: metformin
Gnudi, L., & Ricciardi, C. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_24 · Cited by 3
López, A. A. P., Chávez-Negrete, A., Rodríguez-Lozano, A. L., Gómez-Alarcón, Á. J., Montaño-Velázquez, B. B., Hinojosa, C. A., Sánchez-Hernández, C., Pimentel-Hernández, C., Dehesa-López, E., Romero-Moreno, F., et al. (2026) · Revista Mexicana de Endocrinología Metabolismo y Nutrición · doi:10.24875/rme.m23000030 · Cited by 9
Azhari, H. F., & Dawson, J. (2024) · Frontiers in Stroke · doi:10.3389/fstro.2024.1363954 · Cited by 4
Labban, S. Y., Obaid, N. A., Al-Hulumi, A. H., Labban, S. Y., Jarrar, Y. B., Jamous, Y. F., Mattar, D. S., & Alsaeedi, F. A. (2024) · International Journal of Pharmacology · doi:10.3923/ijp.2024.1151.1162 · Cited by 2
Tan, J., Chiamkunakorn, C., Boonchuay, K., Shi, Y., Braeckman, B. P., & Suthammarak, W. (2025) · PLoS ONE · doi:10.1371/journal.pone.0326100 · Cited by 3
Sun, H., Liu, Z., Li, X., Wen, D., Li, B., & Huang, X. (2025) · Journal of Applied Microbiology · doi:10.1093/jambio/lxaf233 · Cited by 3
Eriksson, J. W., Fanni, G., Lundqvist, M., Jansson, S. P. O., Rådholm, K., Sofizadeh, S., Patsoukaki, V., Nilsson, A., Lindholm, D. P., Rolandsson, O., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70320 · Cited by 4
Gestational Diabetes Mellitus and Future Risk of Cardiovascular Disease
Bhake, R. C., Chittake, V., Lumpatki, S. B., Tiwari, S., & Unnikrishnan, A. G. (2025) · Chronicle of Diabetes Research and Practice · doi:10.4103/cdrp.cdrp_12_25 · Cited by 3
The mineralocorticoid receptor: a new chapter for therapeutic regulation of diabetic cardiomyopathy
Kanki, M., & Young, M. J. (2026) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2026.01.004 · Cited by 3
Metadata
- Authors
- Griffin, S. J., Leaver, J. K., & Irving, G. J.
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- Griffin, Simon J.
- Venue
- Diabetologia
- Published
- 2017-08-02
- Volume
- 60
- Issue
- 9
- Pages
- 1620-1629
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC5552849
- OpenAlex
- W2740802742
- Cited by
- 398
- References
- 45
- Citations by year
- 2026: 13 · 2025: 23 · 2024: 33 · 2023: 31 · 2022: 52 · 2021: 60 · 2020: 75 · 2019: 64 · 2018: 39 · 2017: 8
- FWCI
- 7.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Edge Hill University Research Information Repository (Edge Hill University) (publishedVersion, cc-by)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- University of Cambridge
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- metformin, type 2 diabetes, cardiovascular disease, myocardial infarction, stroke, all-cause mortality, cardiovascular mortality, peripheral vascular disease, ischemic heart disease, UK Prospective Diabetes Study, lifestyle intervention, drug effectiveness, cardiovascular risk reduction, glycemic control, randomized controlled trials, meta-analysis of trials, study heterogeneity, publication bias
- MeSH terms
- Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.